Freeline_Logo_Red_RGB.jpg
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2022 16:01 ET | Freeline Therapeutics Holdings plc
LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory...
Freeline_Logo_Red_RGB.jpg
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
October 04, 2022 07:00 ET | Freeline Therapeutics Holdings plc
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...
Freeline_Logo_Red_RGB.jpg
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2022 17:30 ET | Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
August 09, 2022 07:00 ET | Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
Freeline_Logo_Red_RGB.jpg
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022 16:01 ET | Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
Freeline_Logo_Red_RGB.jpg
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
July 21, 2022 07:00 ET | Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
Freeline_Logo_Red_RGB.jpg
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
July 10, 2022 03:00 ET | Freeline Therapeutics
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) -- Freeline...
Freeline_Logo_Red_RGB.jpg
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:01 ET | Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...
Freeline_Logo_Red_RGB.jpg
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
June 24, 2022 09:32 ET | Freeline Therapeutics
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene...
Freeline_Logo_Red_RGB.jpg
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
June 14, 2022 07:00 ET | Freeline Therapeutics
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen ...